Welcome to our dedicated page for MVIR news (Ticker: $MVIR), a resource for investors and traders seeking the latest updates and insights on MVIR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect MVIR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of MVIR's position in the market.
Medivir AB (MVIR), a pharmaceutical company focused on developing innovative treatments for cancer, has announced that it will host the Q1 Quarterly Results webcast on April 30 at 10 a.m. CET. The webcast has been brought forward due to Nasdaq Stockholm closing earlier. For more information, contact Magnus Christensen, CFO of Medivir AB, at +46 8 5468 3100 or magnus.christensen@medivir.com.
Medivir AB announced that an abstract for the combination of fostrox + Lenvima in hepatocellular carcinoma (HCC) has been accepted for presentation at the European Society for Medical Oncology Gastrointestinal Cancers Congress. The abstract titled 'Liver pharmacodynamics in an open-label phase Ib/IIa study of fostrox in combination with lenvatinib in hepatocellular carcinoma' will be presented at the conference. The presentation will include pharmacodynamic data from patients in the ongoing clinical study, evaluating the impact on normal liver function and DNA damage in tumor cells vs healthy cells. It will also provide an update on efficacy endpoints as the study continues to mature. The poster will be available on Medivir's website after the presentation.
